Search Results - therapeutics+%3e+oncology

125 Results

Sort By:

Novel Strategy to Produce Bi-specific Chimeric Antigen Receptors (UCLA Case No. 2024-169)

Researchers in the Department of Medicine and the Department of Microbiology, Immunology and Molecular Genetics have created novel bi-specific chimeric antigen receptors. BACKGROUND: Chimeric antigen receptors (CARs) are synthetic receptors engineered to redirect T cells towards specific targets on other cells, typically using a single chain antibody....

Published: 11/15/2024 | Inventor(s): Otto Yang

Keywords(s):

Category(s): Therapeutics > Oncology

Small Molecules that Inhibit RNA Binding Protein IGF2BP3 in Cancer (UCLA Case No. 2023-215)

UCLA researchers in the Department of Pathology and Laboratory Medicine have developed small molecules which inhibits the protein IGF2BP3, a highly expressed oncofetal protein in certain cancers, especially in B-acute lymphoblastic leukemia. BACKGROUND: Cancer remains the second leading cause of death in the U.S. Advancements in targeted therapies...

Published: 11/15/2024 | Inventor(s): Dinesh Rao

Keywords(s): blood cancers, Cancer, cancer inhibition, leukemia

Category(s): Therapeutics > Oncology

Methods To Predict the Efficacy of Neoadjuvant Anti-PD-1 Therapy in Resectable Oral-Cavity Squamous Cell Carcinoma and Target Post-Surgical Relapses (UCLA Case No. 2022-039)

UCLA researchers in the School of Medicine have developed a novel therapeutic strategy to improve prognosis of resectable head and neck cancer patients based on clinical studies. BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is an aggressive and recurrent cancer, ranked sixth among common epithelial malignancies worldwide. Over a third...

Published: 11/4/2024 | Inventor(s): Roger Lo

Keywords(s): anti-PD-1, head and neck cancer, head and neck squamous cell carcinoma (HNSCC), Immunotherapy, oral cavity squamous cell carcinoma (OCSCC), resectable tumors

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy

Combination Cancer Therapy Methods and Agents (UCLA Case No. 2024-084)

UCLA researchers from the Department of Medicine, Pathology, & Laboratory Medicine and Molecular & Medical Pharmacology have identified a novel cell-based therapy that leads to enhanced immunotherapy efficacy and overcomes treatment resistance to immune checkpoint blockade in non-small cell lung cancer. BACKGROUND: Non-small cell lung cancer...

Published: 11/4/2024 | Inventor(s): Bin Liu, Steven Dubinett

Keywords(s): anti-tumor immunity, cell-based therapy, Immune checkpoint blockade, Immunotherapy, non-small cell lung cancer, treatment resistance, Tumor microenvironment, Vaccines

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy, Therapeutics > Respiratory And Pulmonary

Interferon Activation Score Is a Biomarker for Immunotherapy in Malignant Glioma Patients (UCLA Case No. 2024-043)

UCLA researchers from the Department of Neurosurgery have characterized immune responses in malignant glioma patients receiving immunotherapy to develop a robust biomarker that will allow prediction of clinical outcomes following treatment. BACKGROUND: Malignant gliomas are the most common primary brain tumors in adults. No cures exist and most gliomas...

Published: 10/23/2024 | Inventor(s): Robert Prins

Keywords(s): adjuvant therapy, Biomarker, Chemotherapy, Clinical Trial, dendritic cell vaccination, Glioblastoma, Glioma, immune response, Immunotherapy, interferon, malignant glioma

Category(s): Diagnostic Markers > Immunology, Diagnostic Markers > Cancer, Therapeutics > Inflammation And Inflammatory Diseases, Therapeutics > Oncology, Therapeutics > CNS and Neurology

Inhibitors of the N-terminal Domain of the Androgen Receptor (UCLA Case No. 2023-075)

Researchers at UCLA under the guidance of Drs. Matthew Rettig and Michael Jung have developed novel molecular compounds that reduce growth of prostate cancer cells. Dr. Jung in collaboration with Dr. Rettig have furthered the development of these compounds by synthesizing a new series of analogues that have similar inhibitory effects. BACKGROUND: Prostate...

Published: 9/23/2024 | Inventor(s): Matthew Rettig, Michael Jung

Keywords(s): androgen receptor therapy, castration resistant prostate cancer, Oncology, Oncology (Small Molecules, Peptides and Antibodies), prostate cancer, small molecules

Category(s): Therapeutics > Oncology, Therapeutics > Oncology > Oncology (Small Molecules)

Compounds and Methods for Treating Cancer by Destroying Cancer Stem Cells (UCLA Case No. 2021-286)

Researchers from UCLA’s Department of Chemistry and Biochemistry and the Department of Radiation Oncology have synthesized a set of compounds for the eradication of cancer stem cells. These compounds are predicted to cross the blood brain barrier and show promise as effective interventions for glioblastoma in both in vitro and in vivo assays. BACKGROUND:...

Published: 7/11/2024 | Inventor(s): Michael Jung, Frank Pajonk

Keywords(s): blood-brain barrier, Brain, Cancer, Cancer stem cells, drug screening, GBM, Glioblastoma, Glioma, new chemical entity

Category(s): Therapeutics > Oncology, Therapeutics > CNS and Neurology, Therapeutics > Stem Cells And Regenerative Medicine

Methods and Compositions for Treating Melanoma (UCLA Case No. 2021-324)

The Graeber Laboratory at UCLA discovered a novel mechanism for treating melanoma using ferroptosis, a type of programmed cell death, that shows promise against therapy resistance. BACKGROUND: Melanoma is a highly aggressive skin cancer that spreads throughout the body and can be fatal if left untreated. Therapies for melanoma range from immunotherapy...

Published: 7/10/2024 | Inventor(s): Thomas Graeber

Keywords(s): Cancer, ferroptosis, Immunotherapy, MAPK signaling, Melanoma, Oncology, Skin, tumor resistance

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy

Multi-Phasic Therapeutic Delivery System (UCLA Case No. 2020-396)

Researchers in the Department of Radiological Sciences at UCLA have conceived a new methodology to overcome obstacles arising after the treatment of tumors by accessing their vascular supply by 1) targeting tumor vessels 2) delivering antineoplastic agents (e.g., chemotherapy or immunotherapy) and 3) delivering anti-angiogenic therapy to reduce blood...

Published: 7/10/2024 | Inventor(s): Antoinette Gomes

Keywords(s): Anti-Angiogenics, Multiphasic and Multitemporal, Oncology, Therapeutics, Vascular therapy

Category(s): Therapeutics > Oncology, Medical Devices

Engineered T Cells Capable of Simultaneous Tumor Targeting and Alteration of Tumor Microenvironment Through Vasculature Normalization (UCLA Case No. 2023-264)

UCLA researchers in the Department of Microbiology, Immunology and Molecular Genetics have built a series of chimeric antigen receptor (CAR)-T cells that target different antigens and secrete different anti-angiogenic proteins. Additionally, researchers also constructed bispecific CARs that respond to tumor antigen and pro-angiogenic molecules. BACKGROUND:...

Published: 6/27/2024 | Inventor(s): Yvonne Chen

Keywords(s): Cancer, Cancer Immunotherapy, CAR-T cell therapy, immunosuppression, Immunosuppressive Drug, Immunotherapy, solid tumors, Tumor microenvironment, tumor vasculature, VEGF

Category(s): Therapeutics > Oncology

1 2 3 4 5 6 7 8 9 10 ...